Balyasny Asset Management L.P. Lowers Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Balyasny Asset Management L.P. cut its stake in Keros Therapeutics, Inc. (NASDAQ:KROS) by 32.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 221,391 shares of the company’s stock after selling 104,043 shares during the period. Balyasny Asset Management L.P. owned 0.55% of Keros Therapeutics worth $3,505,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. MetLife Investment Management LLC lifted its holdings in shares of Keros Therapeutics by 6.0% during the fourth quarter. MetLife Investment Management LLC now owns 18,098 shares of the company’s stock valued at $286,000 after purchasing an additional 1,027 shares during the last quarter. Handelsbanken Fonder AB lifted its holdings in shares of Keros Therapeutics by 11.3% during the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company’s stock valued at $171,000 after purchasing an additional 1,100 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Keros Therapeutics by 19.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company’s stock valued at $136,000 after purchasing an additional 1,372 shares during the last quarter. Virtus ETF Advisers LLC lifted its holdings in shares of Keros Therapeutics by 107.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock valued at $61,000 after purchasing an additional 1,998 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Keros Therapeutics by 2.6% during the fourth quarter. Bank of New York Mellon Corp now owns 97,878 shares of the company’s stock valued at $1,549,000 after purchasing an additional 2,462 shares during the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the business’s stock in a transaction dated Wednesday, April 9th. The stock was purchased at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the transaction, the insider now directly owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. The trade was a 27.01% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 20.60% of the stock is currently owned by insiders.

Keros Therapeutics Trading Down 2.6%

NASDAQ:KROS opened at $13.65 on Monday. Keros Therapeutics, Inc. has a 12 month low of $9.12 and a 12 month high of $72.37. The company has a market cap of $554.39 million, a PE ratio of -2.62 and a beta of 1.32. The company has a 50 day simple moving average of $12.20 and a two-hundred day simple moving average of $24.23.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $211.25 million during the quarter, compared to the consensus estimate of $84.62 million. During the same quarter in the previous year, the firm posted ($1.21) EPS. Research analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on KROS. Oppenheimer lowered their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a report on Thursday, January 16th. Guggenheim reiterated a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Piper Sandler decreased their price objective on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a report on Friday, January 17th. Cantor Fitzgerald lowered shares of Keros Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 21st. Finally, Wedbush restated a “neutral” rating and issued a $15.00 price objective on shares of Keros Therapeutics in a report on Tuesday, April 1st. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Keros Therapeutics has an average rating of “Moderate Buy” and an average price target of $38.67.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.